Grace Therapeutics (NASDAQ:GRCE) Shares Down 0.4% – Here’s What Happened

Grace Therapeutics, Inc. (NASDAQ:GRCE)’s stock price traded down 0.4% during trading on Thursday . The stock traded as low as $2.25 and last traded at $2.29. 27,548 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 91,147 shares. The stock had previously closed at $2.30.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Grace Therapeutics in a research report on Tuesday, February 18th.

Grace Therapeutics Stock Performance

The stock has a market cap of $22.11 million, a price-to-earnings ratio of -1.88 and a beta of 1.19. The company’s 50-day moving average is $3.31.

Grace Therapeutics (NASDAQ:GRCE) last issued its earnings results on Thursday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Research analysts forecast that Grace Therapeutics, Inc. will post -1.06 EPS for the current fiscal year.

About Grace Therapeutics

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.